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Molecular-based detection of bacterial pathogens directly from clinical specimens permits rapid initiation of ef-
fective antimicrobial treatment and adequate patient management. Broad-range polymerase chain reaction
(PCR) ampliﬁcation of the 16S rRNA gene (16S rDNA qPCR) is used inmany diagnostic laboratories as a comple-
ment to cultural identiﬁcation of bacterial pathogens. However, efforts for automation of 16S rDNA PCR
workﬂows are needed in order to reduce turnaround times and to enhance reproducibility and standardization
of the technique. In this retrospective method evaluation study, clinical specimens (N=499) from patients with
suspected bacterial infections were used to evaluate 2 diagnostic semiautomated workﬂows for rapid bacterial
pathogen detection. The workﬂows included automated DNA extraction (QIASymphony), 16S rDNA qPCR, frag-
ment or melting curve analysis, and amplicon sequencing. Our results support the use of the 16S rDNA qPCR and
fragment analysis workﬂow as it enabled rapid and accurate identiﬁcation of bacterial pathogens in clinical
specimens.
© 2018 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Rapid diagnosis of bacterial infections is a key factor for patient man-
agement, and delays in initiating effective antimicrobial treatment result
in increased patientmorbidity andmortality (Iregui et al., 2002). Bacterial
culture takes at least 24 to 48h for bacterial identiﬁcation andmaybe false
negative when fastidious pathogens like Kingella kingae orMycoplasma
spp., noncultivable bacteria such as Coxiella burnetiid, or nonviable bacte-
ria are present in a clinical specimen (Cherkaoui et al., 2009). In contrast,
quantitative polymerase chain reaction (qPCR) detects bacterial DNA re-
gardless of viability, which is particularly important when empiric antibi-
otic therapy has already been administered to patients (Wagner et al.,
2018). Recently, many syndromic point-of-care tests were launched that
enable the detection of a panel of viral, bacterial, and fungal pathogens
(Buss et al., 2015; Leber et al., 2016; Popowitch et al., 2013). However,
syndromic PCR panels or qPCR use primers and probes that target speciﬁc
bacterial species, therebymissing unexpected or rare bacterial pathogens.
In contrast, nonspeciﬁc, broad-range PCR ampliﬁcation of the bacterial
16S rRNAgene (16S rDNAqPCR) enables thedetection of all bacteria pres-
ent in a clinical sample (Bosshard et al., 2004; Rampini et al., 2011;
Sontakke et al., 2009; Srinivasan et al., 2015), though supposedly with
less sensitivity than targeted qPCR (Morel et al., 2015). However, the uni-
versality of 16S rDNA qPCR renders it vulnerable to contamination. All
bacterial DNA present in a clinical sample is ampliﬁed, including the
DNA that is present in extraction chemicals and PCR reagents. This em-
phasizes the need for the use of proper controls (i.e., process and negative
controls that allowmonitoring the DNA background in the chemicals and
reagents) when using 16S rDNA qPCR workﬂows for pathogen detection.
16S rDNA ampliﬁcation in combination with Sanger sequencing has
been established as the standard approach for culture-independent de-
tection of bacterial pathogens in many clinical microbiology laborato-
ries. The main advantages of Sanger sequencing compared with next-
generation sequencing (NGS) platforms are read lengths of up to
1000 bp combined with high accuracy. Moreover, 16S rDNA amplicons
can be rapidly sequenced (8 amplicons per hour) with low per-sample
cost (Lam et al., 2012). However, Sanger sequencing is problematic
when clinical specimens contain multiple bacterial species, such as
stool or respiratory samples or in polymicrobial infections. In such
cases, results obtained by Sanger sequencing are not interpretable and
make it hard or even impossible to identify speciﬁc pathogens. There-
fore, Sanger sequencing is primarily recommended for analysis of clini-
cal specimens from normally sterile body sites. NGS, in contrast, can be
used to identify multiple bacterial species in a clinical specimen. More-
over, laboratories with large sample numbers can use high-throughput
NGS platforms (e.g., from Illumina or Thermo Fischer) that have
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comparatively high sequencing depth despite having short read lengths
(Besser et al., 2017).
In the past years, manual DNA extraction from clinical specimens
and 16S rDNA PCR was combined with polyacrylamide gel electropho-
resis (i.e., CleanGel with silver staining) and Sanger sequencing for bac-
terial identiﬁcation at the Institute of Medical Microbiology, University
of Zurich (Rampini et al., 2011). This workﬂow is time consuming
with a lot of “hands-on-time” from laboratory personnel as DNA extrac-
tion, pipetting of the PCR ampliﬁcation mixture and CleanGel analysis
are performed manually. As a consequence, results are often not deliv-
ered as rapidly as required for proper patient management and correct
antibiotic treatment initiation.
With advances in high-throughput technologies, these steps can be in-
corporated into a robotic liquidhandling system, enabling semiautomation
of 16S rDNA sequencing. Automation of some steps in these workﬂows
like DNA extraction and pipetting of the PCR setup speeds up workﬂows
while enhancing reproducibility and standardization. Recently, dual prim-
ing oligonucleotides (DPO) for sensitive and speciﬁc 16S rDNA qPCR have
been developed (Kommedal et al., 2012). DPO primers typically consist of
a longer 5′ segment that enables stable annealing of the primer and a
shorter 3′ segment that ensures target speciﬁc extension. The 2 functional
segments are connected by 5 consecutive deoxyinosine bases, called poly
(I) linker (Chun et al., 2007).
Thedetectionof 16S rDNAampliﬁcation canbedonebyusing a labeled
probe or an intercalating ﬂuorescent dye. However, as no universal 16S
rDNA qPCR probe is available at present, an alternative represents the
use of SYBR Green® as ﬂuorophore in qPCR ampliﬁcation. This approach
is sensitive, though a disadvantage is that SYBR Green® binds nonspeciﬁ-
cally to all double-stranded DNA molecules present in a clinical sample
(including human DNA, DNA from extraction chemicals, and PCR re-
agents), thereby obscuring quantiﬁcation cycle values in qPCR. Fragment
analyzer capillary electrophoresis or melting curve analysis can be used
to distinguish nonspeciﬁc ampliﬁcation products from 16S rDNA qPCR
products.
In this retrospectivemethod evaluation study, we used clinical spec-
imens from sterile body sites (N= 499) that had been previously ana-
lyzed by culture and a 16S rDNA PCR workﬂow. This established
workﬂow was compared to 16S rDNA qPCR using DPO primers com-
bined with SYBR Green® detection, fragment or melting curve analysis,
and Sanger sequencing (Fig. 1).
2. Materials and methods
2.1. Study design, clinical specimens, and medical record review
The retrospective study included499 clinical specimens fromunique
patients analyzed between 2013 and 2017 at the diagnostic laboratory
of the Institute of Medical Microbiology (IMM), University of Zurich.
Clinical samples were sent to the IMM from secondary and tertiary hos-
pitals in the Zurich metropolitan area (Switzerland, Europe) for
2 to 3 days
Time to result
d) Species identification using
16S rDNA SMARTGene® database
a) Manual DNA extraction
d) Semi-nested 16S rDNA qPCR
e) ABI Sanger sequencing 
16S rDNA qPCR
3’-
5’-
-5’
-3’
b) 16S rDNA qPCR
c) CleanGel silver staining
1 to 2 days
4
h
o
u
r
s
3’-
5’-
-5’
-3’
4
h
o
u
r
s
3
h
o
u
r
s
3
h
o
u
r
s
3
h
o
u
r
s
0
.
5
h
o
u
r
s
e)
3’-
5’-
-5’
-3’
QR
16S rDNA qPCR
 fragment analysis
1 to 2 days 
a) Automated DNA extraction
b) 16S rDNA qPCR
d) ABI Sanger sequencing 
2
h
o
u
r
s
1
.
5
h
o
u
r
s
3
h
o
u
r
s
0
.
5
h
o
u
r
s
e)
3’-
5’-
-5’
-3’
QR
16S rDNA qPCR
melting curve analysis
a) Automated DNA extraction
b) 16S rDNA qPCR
d) ABI Sanger sequencing 
2
h
o
u
r
s
1
.
5
h
o
u
r
s
3
h
o
u
r
s
0
.
5
h
o
u
r
s
85°C           95°C   
c) Melting curve analysis
1
0
 
m
i
n
c) Fragment analysis
1
.
5
 
h
o
u
r
s
1 2 3 4 5 M
Species identification using
16S rDNA SMARTGene® database
Species identification using
16S rDNA SMARTGene® database
Fig. 1. Overview of the diagnostic scheme evaluated in this study for bacterial pathogen detection directly from clinical specimens (R refers to reporter; Q refers to quencher).
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bacterial identiﬁcation by culture and ampliﬁcation of the 16S rRNA
gene (16S rDNA PCR). The specimens were solely from normally sterile
body sites. We included the following sample types: fresh biopsies
(N = 215), punctates and deep wound secretions (N = 213), whole
blood (N = 45), bone marrow (N = 2), cerebrospinal ﬂuid (N = 17),
and bone samples (N = 7). Diagnosis of bacterial infection was
established combining underlying disease and disease history of the pa-
tient, clinical course of disease and interventions, clinical signs and
symptoms of inﬂammation, additional diagnostics if available (such as
radiology and pathology reports), andmicrobiological ﬁndings (micros-
copy, culture, PCR results, detection of fungal or viral pathogens) includ-
ing detailed consultations with the treating physicians. Therefore, all
included specimens in the retrospective study were obtained from pa-
tients with a “conﬁrmed bacterial infection” or “no bacterial infection”.
2.2. Culture, microscopy, and 16S rDNA PCR workﬂow
Cultures were performed as described previously (Bosshard et al.,
2003, 2004). In brief, aerobic culture was performed using Columbia
blood agar, MacConkey agar, Columbia CNA blood agar, and Crowe
agar (Becton Dickinson, Allschwil, Switzerland). Anaerobic culture was
done using Brucella agar, kanamycin–vancomycin agar, and phenylethyl
alcohol agar (Becton Dickinson, Allschwil, Switzerland), and thioglycolate
broth was used for enrichment cultures. Agar plates were examined for
growth after 24, 48, and 72 h. Cultures were assessed as negative if no
bacterial growth was visible after 10 days of incubation in the liquid en-
richment medium. Liquid samples were inoculated into aerobic and an-
aerobic BacT/Alert Blood Culture ﬂasks (BioMérieux, Marcy-l'Etoile,
France) for enrichment cultures and incubated in the BacT/Alert system
for 6 days. Gram stains of clinical specimens were prepared according to
standard procedures.
DNA extraction from clinical specimens and 16S rDNA PCR ampliﬁca-
tion were performed as described previously (Bosshard et al., 2003).
Escherichia coli chromosomal DNA was used as positive control, and a
water sample was used as negative control in each 16S rDNA PCR run.
16S rDNA PCR ampliﬁcation products were visualized by polyacrylamide
gel electrophoresis (CleanGel 10% 52S, ETC GmbH, Kirchentellinsfurt,
Germany) combined with silver staining. Subsequently, a seminested
PCR was performed; 16S rDNA PCR products were puriﬁed with the
QIAquick PCR puriﬁcation kit (Qiagen, Hombrechtikon, Switzerland)
and sequenced with forward primer BAK11w (5′-AGTTTGATC[A/C]TGG
CTCAG) using the BigDye kit (Life Technologies, Zug, Switzerland) and
an automated DNA sequencer (ABI Prism 3130 Genetic Analyzer; Life
Technologies, Zug, Switzerland). Bacterial identiﬁcation was done using
the 16S rDNA SmartGene IDNS custom platform following the identiﬁca-
tion guidelines published previously by Bosshard et al. (2003).
2.3. qPCR ampliﬁcation of the 16S rRNA gene
DNA from clinical specimens was retrospectively analyzed by two
16S rDNAqPCRworkﬂows (Fig. 1). For 16S rDNA qPCR, 5 μL of extracted
DNA was added to a mixture consisting of 8.5 μL Roche water (Roche,
Rotkreuz, Switzerland), 4 μL of a LightCycler® DNA multiplex master
mix (Roche), 0.5 μM of each DPO® primer (DPO®-F: 5′-
AGAGTTTGATCMTGGCTCA-I-I-I-I-I-AACGCT-3′, DPO®-R: 5′-
CGCGGCTGCTGGCA-I-I-I-A-I-TTRGC-3′) (Kommedal et al., 2012), and
1 μM of SYBR Green (Sigma Aldrich, Buchs, Switzerland). qPCR ampliﬁ-
cation was done with a Lightcycler 480-II instrument (Roche). Cycling
parameters included an initial denaturation for 5 min at 95 °C, followed
by 45 cycles of 5 s at 95 °C, 15 s at 60 °C, and 15 s at 72 °C. The qPCR
yielded a 500-bp PCR amplicon covering the V1 to V3 region of the
16S rRNA gene. All clinical specimens showed an ampliﬁcation curve
in qPCR analysis as even minimal traces of DNA were ampliﬁed and
16S rDNA fragments were subsequently analyzed by fragment or melt-
ing curve analysis. In each Lightcycler 480-II run, E. coli chromosomal
DNAwas included as positive control, and a water sample was included
as negative control.
2.4. Fragment and melting curve analysis
Fragment analysis was done on a fragment analyzer automated CE
system (Advanced Analytical Technologies Inc., Heidelberg, Germany)
according to the manufacturer's instructions using the Fragment
Analyzer-ds DNA 905 Kit. Clinical specimens were assessed as positive
if they showed a fragment length of 450 bp to 500 bp and revealed
greater ﬂuorescence intensity (FI) than the water negative control.
Melting curve analysis was done on a Lightcycler 480-II instrument
starting from 40 °C and increasing the temperature by 1.5 °C per second
until a ﬁnal temperature of 97 °C was reached. Clinical specimens were
evaluated as positive in melting curve analysis if they showed a maxi-
mum –(d/dT) FI in the range of 85 °C to 95 °C that was greater than
the maximum –(d/dT) FI of the water negative control.
2.5. Sequencing of 16S rDNA qPCR ampliﬁcation products
16S rDNAqPCR products thatwere assessed as positive in fragment or
melting curve analysis were puriﬁed with the QIAquick PCR puriﬁcation
kit and sequenced using the BigDye kit and an automated DNA sequencer
(ABI Prism 3130-Genetic Analyzer, Life Technologies, Zug, Switzerland).
Sanger electropherograms were visually examined (regularity of base
spacing, distribution of peak heights, occurrence and height of minor
background peaks). Any part of the electropherogram that showed irreg-
ularities (e.g., high background noise, irregular base spacing, and peak
height distributions) was excluded from the reported result. Accurate
bacterial identiﬁcationwas achieved by analyzing sequences with a qual-
ity score N 20 (“NQ20”) that covered at least 400 bp of the respective bac-
terial 16S rRNA gene in the 16S rDNA SmartGene IDNS custom platform
(SmartGene, Lausanne, Switzerland). Species- and genus-level identiﬁca-
tion was done following the criteria published by Bosshard et al. (2003).
Contamination of reagents and materials with traces of bacterial DNA
may adversely affect the speciﬁcity of broad-range PCR (Loefﬂer et al.,
1999). We used 3 criteria to uncover environmental contamination and
to strictly categorize samples as negative: 1) no distinct 16S rDNA PCR
fragment could be observed in the CleanGel, and 16S rDNA qPCR frag-
ments revealed lower FI in fragment analysis or lower –(d/dT) FI inmelt-
ing curve analysis than the water negative control and 2) bacterial
identiﬁcation in a clinical specimen was identical to the identiﬁed bacte-
rium in the water negative control (in this study, identiﬁcation of
Aquabacterium commune or Achromobacter sp. DNA background).
2.6. Statistics
A synopsis of clinical ﬁndings (disease history, clinical picture) and
laboratory results (microscopy, 16S rDNA PCR, bacterial culture) includ-
ing consultation with the treating physician was used as gold standard
to categorize patients with a “clinically conﬁrmed bacterial infection” or
“no bacterial infection.” On the basis of this composite diagnostic mea-
sure, we used the 2 × 2 contingency table to calculate the agreement be-
tween the 3 different diagnostic workﬂows (Cohen, 1960; Landis and
Koch, 1977).
2.7. Ethics statement
The study was conducted according to good laboratory practice and
in accordance with the Declaration of Helsinki and national and institu-
tional standards. The act onmedical research involving human subjects
does not apply to this study. In this study, solely extracted DNA from
clinical specimens and anonymized health-related data were used;
therefore, no consent from the ethics committee was required.
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2.8. Availability of data
The datasets generated and analyzed during the current study are
available from the corresponding author on reasonable request.
3. Results
3.1. Diagnostic performance of the 16S rDNA qPCR and fragment analysis
workﬂow
In total, 499 clinical specimenswere retrospectively analyzed by 16S
rDNA qPCR, fragment analysis, and Sanger sequencing and compared to
results from the 16S rDNA PCRworkﬂow (Fig. 1). In 362/499 specimens
(72%), no bacterial identiﬁcation was achieved, while in 137/499 speci-
mens (28%), a bacterial pathogenwas identiﬁed (Table 1). In each assay,
8 specimens frompatientswith a clinically conﬁrmedbacterial infection
were missed (Tables 1, S1).
In 299/499 specimens, no distinct 16S rDNA PCR fragment was visible
in the CleanGel, and these specimenswere assessed negative. A 16S rDNA
PCR ampliﬁcation product in the CleanGel was present in 200/499 speci-
mens. In 63 of these specimens, bacterial identiﬁcation was not possible
or revealed known environmental contaminants (Aquabacterium com-
mune or Achromobacter sp.), while bacterial pathogens were identiﬁed
in 137 specimens. Using fragment analyses, 289/499 specimens revealed
an FI that was lower than the FI in the water negative control and there-
forewere assessed negative. In 210/499 specimens, an FI thatwas greater
than the FI of the water negative control was revealed, and the corre-
sponding PCR products were sequenced (Fig. 2). In 137 of those speci-
mens, a bacterial pathogen was identiﬁed, and in 73 of the sequenced
specimens, bacterial identiﬁcation was not possible (i.e., weak peaks or
multiple overlying peaks in the Sanger electropherograms) or pointed
to known environmental contaminants.
A diverse range of bacterial genera was concordantly identiﬁed by
16S rDNA PCR and 16S rDNA qPCR including Anaerococcus, Actinomyces,
Borrelia, Clostridium, Enterococcus, Enterobacter, Fusobacterium, Hae-
mophilus, Klebsiella, Moraxella, Neisseria, Pseudomonas, Providencia,
Streptococcus, and Staphylococcus. The 5 most prevalent bacterial spe-
cies identiﬁed were Enterococcus faecalis, Staphylococcus epidermidis,
Streptococcus pyogenes, Pseudomonas aeruginosa, and Kingella kingae.
The 8 bacterial pathogens that were identiﬁed by the 16S rDNA PCR
but missed by the 16S rDNA qPCR workﬂow included Anaerococcus sp.,
Granulicatella adiacens, Cutibacterium acnes, Streptococcus dysgalactiae,
Streptococcus intermedius, Yersinia sp., and 2 specimens withmixed infec-
tions (1 specimen with Porphyromonas endodontalis, Parvimonas micra
and Clostridium sp.; 1 specimen with Enterobacteriaceae and Clostridium
perfringens) (Table S1). In 8 specimens, bacterial pathogens were solely
identiﬁed by the 16S rDNA qPCR workﬂow and included Anaerococcus
lactolyticus, Enterobacter aerogenes, Enterobacter cloacae complex, Kingella
kingae, Cutibacterium acnes, Staphylococcus epidermidis, Streptococcus
mitis/oralis group, and Streptococcus pneumoniae (Table S1). In 2 of these
specimens, culture conﬁrmed the results obtained by the 16S rDNA
qPCRworkﬂow. In 3 specimens, culturewas foundnegative, and in the re-
maining specimens, culture was not performed.
Overall, a similar proportion of negative specimens were unneces-
sarily sequenced in the 16S rDNA PCR and 16SrDNA qPCR and fragment
analysis workﬂow, and also sensitivity was comparable as both
workﬂows did not identify bacterial pathogens in an equal number of
clinical specimens. The agreement of the old 16S rDNA PCR and the
new 16S rDNA qPCR and fragment analysis workﬂow for the diagnosis
of bacterial infections was 97% using a composite diagnostic measure
combining clinic and microbiology results as the gold standard (Table 1).
3.2. Diagnostic performance of the 16S rDNA qPCR and melting curve anal-
ysis workﬂow
A subset of 330 of the 499 clinical specimenswas analyzed by apply-
ing all 3 diagnostic workﬂows (Fig. 1, Table 2).
In melting curve analysis, 146/330 specimens showed a maximum –
(d/dT) FI that was lower than the –(d/dT) FI of thewater negative control
and therefore were assessed negative. In 184/330 specimens, a –(d/dT) FI
that was greater than the –(d/dT) FI of the water negative control was
shown, and the corresponding 16S rDNA qPCR products were
Table 1
Comparison of the performance of the old (16S rDNA PCR, CleanGel analysis, ABI sequenc-
ing) and the new diagnostic workﬂow (16S rDNA qPCR, fragment analysis, ABI sequenc-
ing) in 499 clinical specimens. A composite diagnostic measure combining clinic and
microbiology results was used as gold standard.
Clinical and
microbiological data
Positive Negative
16S rDNA PCR, CleanGel, sequencing Positive 137 0
Negative 8 354
16S rDNA qPCR, fragment analysis,
sequencing
Positive 137 0
Negative 8 354
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Fig. 2. Relative ﬂuorescence intensities (FI of the sample/FI of the water negative control)
of the 16S rDNA qPCR ampliﬁcation products in fragment analysis are displayed and
categorized based on the results from the old (16S rDNA PCR, CleanGel, sequencing) and
the new (16S rDNA qPCR, fragment analysis, sequencing) diagnostic workﬂows.
Table 2
Comparison of the performance of 3 diagnostic workﬂows for bacterial pathogen detec-
tion in 330 clinical specimens. A composite diagnostic measure combining clinic and mi-
crobiology results was used as gold standard.
Clinical and
microbiological data
Positive Negative
16S rDNA, Clean Gel, sequencing Positive 108 0
Negative 5 217
16S rDNA qPCR, fragment analysis,
sequencing
Positive 111 0
Negative 2 217
16S rDNA qPCR, melting curve analysis,
sequencing
Positive 103 0
Negative 10 217
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subsequently sequenced (Fig. 3). In 103 of those specimens, a bacterial
pathogen was identiﬁed, and in 81 of the sequenced specimens, bacterial
identiﬁcation was not possible (i.e., weak peaks or multiple overlying
peaks in the Sanger electropherograms) or pointed to known environ-
mental contaminants (Aquabacterium commune or Achromobacter sp.;
N= 12).
In 10 specimens, bacterial pathogens could not be identiﬁed by the
16S rDNA qPCR and melting curve analysis workﬂow and included
Anaerococcus lactolyticus, Anaerococcus octavius (N= 2), Borrelia afzelii,
Granulicatella adiacens, Kingella kingae, Staphylococcus aureus (N= 2),
Streptococcus gordonii, and Streptococcus intermedius (Table S2).
Overall, melting curve analysis showed unspeciﬁc detection of 16S
rDNA qPCR fragments, and consequently a high proportion (25%) of
negative specimens were unnecessarily sequenced. Moreover, melting
curve analysis missed 10 specimens from patients with clinically con-
ﬁrmed bacterial infections and therefore showed less sensitive detec-
tion of 16S rDNA qPCR fragments than CleanGel and fragment analysis.
4. Discussion
Rapid detection of bacterial pathogens results in improved patient
management, earlier initiation of effective treatment, a decrease in hos-
pitalization time, and reduced costs for the health care system (Maurer
et al., 2017). The primary aim of this study was to assess a more rapid
16S rDNA qPCR and fragment analysis screening for the diagnosis of
acute bacterial infections and to provide evidence-based data showing
that gel-based visualization methods can be replaced. The proposed di-
agnostic workﬂow offers a higher degree of automation and standardi-
zation and improves routine diagnostics by lowering turnaround time.
Furthermore, it enhances quality and reproducibility by reducing inter-
observer variability. Automated DNA extraction (batches of 24 clinical
samples can be analyzed per run) and pipetting of the qPCR setup
(i.e., on the QIASymphony) reduce confusion of samples and errors
occurring while pipetting the samples (reagents are not added, too lit-
tle/high volumes are added, etc.). Reports are created automatically on
the fragment analyzer, and assessment of sample positivity as shown
in Fig. 2 can be performed with simple data analysis tools like Excel. In
contrast, the CleanGel needs visual inspection and evaluation if 16S
rDNA PCR bands from clinical specimens are stronger than the negative
control band, which leaves great scope for personal interpretation and
leads to high interobserver variability.
When comparing all 3 diagnostic workﬂows, 16S rDNA qPCR in
combination with fragment or melting curve analysis offers the most
rapid pathogen detection (less than 1 working day to assess a clinical
specimen as negative and 1.5 days to identify the bacterial pathogen
by 16S rDNA sequencing). In contrast, the 16S rDNA PCR workﬂow
takes 2 days to assess specimens as negative and 2.5 days until bacterial
identiﬁcation is completed.When comparing the overall costs of thedif-
ferent workﬂows, the 16S rDNA PCR workﬂow had the highest per-
sample cost (20 € for DNA extraction chemicals and PCR reagents [in-
cluding controls] and 16 € for Sanger sequencing), followed by the
16S rDNA qPCR and fragment analysis workﬂow (15 € for extraction
chemicals and PCR reagents [including controls] and 16 € for Sanger se-
quencing) and the 16S rDNA qPCR andmelting curve analysis workﬂow
(13 € for extraction chemicals and PCR reagents [including controls] and
16 € for Sanger sequencing).
In all 3 workﬂows, there were a high proportion (13% to 25%) of se-
quenced specimens that yielded uninterpretable sequences or were
identiﬁed as environmental contaminants. This emphasizes the need
for proper controls in the 16S rDNA PCR and 16S rDNA qPCR, respec-
tively, in order to avoid false-positive identiﬁcations due to background
DNA from chemicals and reagents. Moreover, further attempts should
beundertaken to reduce theDNAbackground in chemicals and reagents
used for broad range applications.
The 16S rDNA qPCR and melting curve analysis workﬂow revealed
the lowest sensitivity, whereas the other 2workﬂows revealed identical
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Fig. 3. Relative ﬂuorescence intensities (maximum –(d/dT) FI of the sample/ maximum –(d/dT) FI of the water negative control) of the 16S rDNA qPCR ampliﬁcation products in melting
curve analysis are displayed and categorized as positive or negative based on a composite diagnostic measure combining clinic and microbiology results.
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sensitivity. Eight clinical specimens were assessed as positive in the 16S
rDNA PCR and negative in the 16S rDNA qPCR and fragment analysis
workﬂow. Three of these 8 specimens showed a ﬂuorescence intensity
in fragment analysis that was lower than the ﬂuorescence intensity of
the water negative control. Review of the original silver stained
CleanGel showed rather weak PCR bands for these three samples. If
the DNA yield is low in the clinical specimen, prolonged freezing and
thawing of genomic DNA may lead to progressive DNA degradation
(Shao et al., 2012) and potentially explain the inability to identify the
bacterial pathogens by 16S rDNA qPCR and subsequent sequencing.
One advantage of agarose or polyacrylamide-gel-based detection
methods is that single bands can be cut from the gel, thereby enabling
species identiﬁcation even in mixed infections. Newer bioinformatic
tools like the RipSeq web application (Pathogenomix, Santa Cruz, CA,
USA) can be used to analyze overlaying DNA chromatograms but in
our experience only delivered bacterial species identiﬁcationwith a suf-
ﬁcient degree of certainty if mixed samples did not contain more than 2
different species. In our opinion, this disadvantage of the 16S rDNA
qPCR and fragment analysis workﬂow is negligible as mixed infections
occurred only in 2 of 499 clinical specimens.
5. Conclusion
The 16S rDNA qPCR and fragment analysis workﬂow has a fast time-
to-result (less than 1working day to assess a clinical specimen as negative
and less than 1.5 days to obtain species identiﬁcation by 16S rDNA se-
quencing). A key advantage of this new workﬂow is that it does not re-
quire time-consuming seminested PCR and CleanGel analysis. Moreover,
it allows for a high degree of automation and standardization as sample
positivity is assessed using bioinformatic procedures in fragment analysis.
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